We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 274

A Modern Melody for the Music Industry: The Music Modernization Act Is Now the Law of the Land
  • K&L Gates
  • USA
  • October 11 2018

On October 11, 2018, President Trump signed the Orrin G. Hatch-Bob Goodlatte Music Modernization Act (“MMA”) into law. The MMA is intended to


USPTO Says Overlapping Range In Prior Art Insufficient to Invalidate Method of Treatment Patent
  • Dechert LLP
  • USA
  • April 13 2018

Pharmaceutical patents frequently claim treatment methods that utilize a range of amounts or concentrations for the active ingredient or excipients


Judge Stark (D. Del.) Holds Generic Label is Insufficient to Prove Induced Infringement
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • April 9 2018

Following a seven-day trial last year, a jury found that Teva willfully induced infringement of claims of U.S. Patent


Rituxan Patent Spared by Failure to Establish Product Label as “Printed Publication”
  • Marshall Gerstein & Borun LLP
  • USA
  • March 26 2018

A patent relating to a method of treating rheumatoid arthritis using rituximab recently survived its fourth IPR challenge. Celltrion, Inc. v. Biogen


Is Your Short Term Disability (STD) Covered by ERISA?
  • Graydon Head & Ritchey LLP
  • USA
  • March 14 2018

Generally, ERISA covers any plan, fund, or program that provides sickness, accident, or disability benefits. This would include all short term


Trump Administration Rejects (Nicely) Idaho’s Attempt to Skirt ACA
  • Crowell & Moring LLP
  • USA
  • March 12 2018

On Thursday, March 8, the Trump Administration rejected Idaho’s plan to sell health plans that do not include the consumer protections required by the


Efforts to Cut Drug Prices in Medicaid
  • Manatt Phelps & Phillips LLP
  • USA
  • February 27 2018

Over the past five years, the budgets of state Medicaid programs have been challenged by the introduction of new high-cost drugs into the marketplace


Capturing Inventions from FDA Label Changes
  • Banner & Witcoff Ltd
  • USA
  • February 14 2018

The U.S. Court of Appeals for the Federal Circuit on January 9, 2018, heard oral arguments in Praxair Distribution, Inc. v. Mallinckrodt Hospital


Not So Common Sense? Reliance on Common Sense to Establish Obviousness
  • Jones Day
  • USA
  • February 13 2018

In KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398, 421 (2007), the Supreme Court stated that “common sense” can be considered in reaching a conclusion


Construing a Continuum of Harassing Behaviors
  • Duane Morris LLP
  • USA
  • January 23 2018

We hear many people use the terms "sexual misconduct" or "sexual harassment" to describe a continuum of harassing behaviors. Further, more and more